Description
GoodRx’s $28.5 Million Subscription Engine — Recurring Revenue Gains Momentum!
GoodRx Holdings, Inc. reported second quarter 2026 results that highlighted ongoing strategic shifts and growth in key areas amid a changing healthcare landscape. Total revenue reached $200.4 million with an adjusted EBITDA of $63.7 million, reflecting a margin of 31.8%. The company raised its full-year revenue guidance to between $790 million and $805 million and adjusted EBITDA guidance to $240 million–$250 million, driven by strong performance in its Pharma Direct and subscription offerings. Pharma Direct grew 76% year-over-year to $61.6 million. The growth was supported by expanding partnerships with pharmaceutical manufacturers and an increase in consumer direct pricing programs, now exceeding 135 across various therapeutic categories. Notably, weight loss drugs like GLP-1 therapies remain a significant driver. The segment benefited from product launches including new GLP-1 oral formulations and intensified manufacturer support amidst ongoing coverage variability such as the new Medicare bridge pricing program.
